Abstract
The fixed dose combination of sitagliptin 50 mg and metformin 850 mg (Janumet ®), is indicated for the treatment of type 2 diabetes mellitus in addition to diet and exercise to improve glycemic control in patients treated with metformin alone. Methods: We report a 69-year-old man with type 2 diabetes that developed sudden loss of eyebrows and eyelashes about 4 months after the beginning of Janumet®.
Clinical and laboratory findings excluded the presence of systemic or skin diseases able to induce these manifestations, while the Naranjo probability scale documented a possible association between the drug and the adverse drug reaction.Keywords: Adverse drug reaction, metformin, sitagliptin, type 2 diabetes mellitus.
Current Drug Safety
Title:Loss of Eyebrows and Eyelashes During Concomitant Treatment with Sitagliptin and Metformin
Volume: 12 Issue: 1
Author(s): Elena Succurro, Caterina Palleria, Mariafrancesca Ruffo, Raffaele Serra, Franco Arturi and Luca Gallelli
Affiliation:
Keywords: Adverse drug reaction, metformin, sitagliptin, type 2 diabetes mellitus.
Abstract: The fixed dose combination of sitagliptin 50 mg and metformin 850 mg (Janumet ®), is indicated for the treatment of type 2 diabetes mellitus in addition to diet and exercise to improve glycemic control in patients treated with metformin alone. Methods: We report a 69-year-old man with type 2 diabetes that developed sudden loss of eyebrows and eyelashes about 4 months after the beginning of Janumet®.
Clinical and laboratory findings excluded the presence of systemic or skin diseases able to induce these manifestations, while the Naranjo probability scale documented a possible association between the drug and the adverse drug reaction.Export Options
About this article
Cite this article as:
Succurro Elena, Palleria Caterina, Ruffo Mariafrancesca, Serra Raffaele, Arturi Franco and Gallelli Luca, Loss of Eyebrows and Eyelashes During Concomitant Treatment with Sitagliptin and Metformin, Current Drug Safety 2017; 12 (1) . https://dx.doi.org/10.2174/1574886311666161014125536
DOI https://dx.doi.org/10.2174/1574886311666161014125536 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effect of Non-antihypertensive Drugs on Endothelial Function in Hypertensive Subjects Evaluated by Flow-mediated Vasodilation
Current Vascular Pharmacology Microdialysis in Drug Discovery
Current Drug Discovery Technologies Acute Myocarditis in Children: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Current Cardiology Reviews Adiponectin as a Regulator of Vascular Redox State: Therapeutic Implications
Recent Patents on Cardiovascular Drug Discovery The Role of the Stress-Related Anti-Inflammatory Hormones ACTH and Cortisol in Atherosclerosis
Current Vascular Pharmacology Epidemiology and Costs of Hypertension-related Disorders
Current Pharmaceutical Design Hypertension and Angiogenesis
Current Pharmaceutical Design The Role of Statins in Oxidative Stress and Cardiovascular Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Bioresorbable Vascular Scaffold: Our Initial Experience
Applied Clinical Research, Clinical Trials and Regulatory Affairs Approaches to the Management of Acute Kidney Injury in Children
Recent Patents on Biomarkers Endothelial Dysfunction: Methods of Assessment & Implications for Cardiovascular Diseases
Current Pharmaceutical Design Angiogenetic Potential of Ad2/Hif-1α/Vp16 after Regional Application in a Preclinical Pig Model of Chronic Ischemia
Current Vascular Pharmacology Chronic Complications of Diabetes Mellitus: A Mini Review
Current Diabetes Reviews Targets Involved in Cardioprotection by the Non-Anesthetic Noble Gas Helium
Current Drug Targets Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance
Current Pharmaceutical Design Protein Kinase C Isozymes: Memory Therapeutic Potential
Current Drug Targets - CNS & Neurological Disorders Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury
Current Medicinal Chemistry